| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $105.71 | $113.53B | N/A |
Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice
http://www.zacks.com/stock/news/376711/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-ZC-FT-376711
Apr 10, 2019 - Lilly (LLY) could produce exceptional returns because of its solid growth attributes.
0
United Therapeutics Discontinues PAH Drug After Study Fails
http://www.zacks.com/stock/news/373203/united-therapeutics-discontinues-pah-drug-after-study-fails?cid=CS-ZC-FT-373203
Apr 09, 2019 - United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
0
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
http://www.zacks.com/stock/news/371759/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-ZC-FT-371759
Apr 06, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
0
Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
http://www.zacks.com/stock/news/371728/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-ZC-FT-371728
Apr 05, 2019 - Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.
0
Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval
http://www.zacks.com/stock/news/371316/dow-30-stock-roundup-wba-q2-earnings-disappoint-pfe-lung-cancer-drug-gets-eu-approval?cid=CS-ZC-FT-371316
Apr 05, 2019 - The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.
0
AVEO Reports Positive Results on Leukemia Drug, Shares Up
http://www.zacks.com/stock/news/369340/aveo-reports-positive-results-on-leukemia-drug-shares-up?cid=CS-ZC-FT-369340
Apr 02, 2019 - AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.
0
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
http://www.zacks.com/stock/news/369336/mercks-keytruda-gets-nod-for-first-line-lung-cancer-in-china?cid=CS-ZC-FT-369336
Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
0
3 Big Pharma Stocks to Add to Your Portfolio This April
http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-ZC-FT-368171
Apr 01, 2019 - The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
0
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals
http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-ZC-FT-367176
Mar 29, 2019 - AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
0
Lilly (LLY) Signs New Immunology Deal With Private Biotech
http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-ZC-FT-365638
Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
0